| 0 (0%) | 11-11 15:53 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.72 | 1-year : | 10.19 |
| Resists | First : | 7.46 | Second : | 8.72 |
| Pivot price | 7.15 |
|||
| Supports | First : | 6.56 | Second : | 6 |
| MAs | MA(5) : | 7.14 |
MA(20) : | 7.06 |
| MA(100) : | 8.02  |
MA(250) : | 8.25 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 69.9 |
D(3) : | 65.3 |
| RSI | RSI(14): 51.7 |
|||
| 52-week | High : | 11.31 | Low : | 6 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ BCRX ] has closed below upper band by 33.6%. Bollinger Bands are 37.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.28 - 7.31 | 7.31 - 7.34 |
| Low: | 7.01 - 7.04 | 7.04 - 7.07 |
| Close: | 7.15 - 7.2 | 7.2 - 7.25 |
Mon, 10 Nov 2025
BioCryst Pharmaceuticals (BCRX): Assessing Valuation After Earnings Beat and Positive ORLADEYO Clinical Updates - simplywall.st
Mon, 10 Nov 2025
BCRX stock momentum explained - 2025 Sector Review & Real-Time Market Sentiment Reports - newser.com
Mon, 10 Nov 2025
Trading the Move, Not the Narrative: (BCRX) Edition - news.stocktradersdaily.com
Sun, 09 Nov 2025
How BCRX stock benefits from strong dollar - Treasury Yields & AI Forecasted Stock Moves - newser.com
Sun, 09 Nov 2025
Why BCRX stock remains on watchlists - Market Movers & Accurate Intraday Trade Tips - newser.com
Wed, 05 Nov 2025
Citizens Maintains BioCryst Pharmaceuticals (BCRX) Market Outperform Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 211 (M) |
| Shares Float | 196 (M) |
| Held by Insiders | 1.1 (%) |
| Held by Institutions | 99 (%) |
| Shares Short | 30,770 (K) |
| Shares Short P.Month | 28,320 (K) |
| EPS | -0.19 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -2.01 |
| Profit Margin | -6.5 % |
| Operating Margin | 18.2 % |
| Return on Assets (ttm) | 7.4 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 49.4 % |
| Gross Profit (p.s.) | 1.76 |
| Sales Per Share | 2.64 |
| EBITDA (p.s.) | 0.27 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 17 (M) |
| Levered Free Cash Flow | 54 (M) |
| PE Ratio | -40.31 |
| PEG Ratio | 0 |
| Price to Book value | -3.61 |
| Price to Sales | 2.73 |
| Price to Cash Flow | 90.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|